You are here

Angiochem appoints David Scheer to its Board Of Directors


Montreal, Canada – Angiochem a clinical-stage biotechnology company developing drugs that are uniquely capable of crossing the blood-brain barrier through LRP-1 targeting, announced today it has appointed David Scheer to its Board of Directors. Mr. Scheer, who is President of Scheer & Company, Inc., a firm focused on life science venture capital, corporate strategy, and transactional advisory services, was involved in the founding and had been a member of the Board of a number of biotechnology companies including, ViroPharma, Inc. (NASDAQ:VPHM), OraPharma, Inc. (acquired by Johnson & Johnson in 2003), and Esperion Therapeutics, Inc. (of which he was Chairman, acquired by Pfizer in 2004).

“I am pleased that David Scheer, with his considerable experience in life science business development, has joined the Angiochem board,” commented Jean-Paul Castaigne, MD, President and CEO of Angiochem. “Through his board appointments and over the course of his extensive career, Mr. Scheer has added significant value to a number of biotechnology organizations by guiding them through corporate alliances, licensing arrangements, divestments, acquisitions and mergers .”

David Scheer founded Scheer & Company in 1981 and from 1991 through 1999, Mr. Scheer was affiliated with the health care investing team at Oak Investment Partners. He has served as a member of the Leadership Council of the Harvard School of Public Health, and as a member of the Advisory Committee to the Harvard Malaria Initiative. He has helped to launch, and currently serves as Chair of “The Unfinished Agenda in Infectious Diseases”, an initiative at the Harvard School of Public Health focusing on neglected diseases. In 2007, he was awarded the Atlas Award for Venture Capital from the Connecticut Union for Research Excellence (CURE, of which he also serves as a member of the Board), and in 2009, he received the Venture Capital Leadership Award from the Connecticut Venture Group. He received his A.B. cum laude from Harvard College, and an M.S. from Yale University.

Scheer has served on many public and privately-held biotechnology company Boards. His current board relationships include Achillion Pharmaceuticals, Inc. (of which he is Chairman, NASDAQ, “ACHN”), Tengion, Inc. (of which he is Chairman, NASDAQ, “TNGN”), Aegerion Pharmaceuticals, Inc. (of which he is Chairman), Optherion, Inc. (of which he is Chairman), and Axerion Therapeutics, Inc. (of which he is Chairman).

“Angiochem’s EPiC technology platform has tremendous potential to treat a range of CNS-related disorders by exploiting LRP-1 receptor-mediated transcytosis to cross the blood brain barrier and effectively deliver therapeutics to the brain ," said Mr. Scheer. “I am honoured to have the opportunity to provide guidance and insights to Dr. Castaigne and the rest of the Angiochem leadership team as they continue to advance their lead programs and pursue value-creating external collaborations.”

About AngioChem // Angiochem is a clinical-stage biotechnology company discovering and developing new breakthrough drugs that are uniquely capable of crossing the blood-brain barrier (BBB) to treat brain diseases. The company’s proprietary Engineered Peptide Compounds (EPiC) technology creates drugs that cross the BBB and reach therapeutic concentration in the brain, by harnessing naturally-occurring receptors on the surface of the BBB. Angiochem’s lead product candidate, ANG1005 is in two separate clinical studies in patients with brain cancers and cancer metastases. Additionally, Angiochem is developing a deep and broad product pipeline, including small and large molecules, for the potential treatment of a wide range of CNS diseases, including neurodegenerative and metabolic diseases, brain cancer, psychiatric disorders and many others. Founded in 2006, Angiochem maintains headquarters in Montreal, Canada. For additional information about the Company, please visit :